Implications of recent news flow
The recent news flow on Kinarus’ lead product KIN001 has bolstered its profile for the treatment of ambulatory COVID-19 patients. In addition, the outlook for the main events for KIN001 – the anti-inflammatory and anti-fibrotic indications – on which most of our valuation is based, have also been boosted by a new US patent allowance.Some investors may wonder why the KINFAST Phase 2 study in mild to moderate ambulatory COVID-19 patients is continuing. There is a good reason, as other approved agents to treat COVID-19 also aimed high, failed in hospitalised patients, but have shown efficacy in earlier-stage COVID-19.
The rationale for the continuation of KINFAST is therefore solid and has been further bolstered by the recent demonstration of KIN001’s strong preclinical antiviral activity against the currently circulating SARS-CoV-2 Omicron subvariants BA.2 and BA.5.
In our recent initiation we led with wet age-related macular degeneration (wAMD) and idiopathic pulmonary fibrosis (IPF) as the main indications for KIN001, which now comprise 91% of our valuation. Kinarus’s recent notice of allowance for its US patent on KIN001 in ophthalmic diseases will help ring-fence their intellectual property in those indications.
Our fair valuation of Kinarus remains at CHF96.0m, or CHF0.09 per share.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.